- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-3-2-mer
- Ligands
- 16 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)(Non-covalent)
- 20 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
NAG.17: 4 residues within 4Å:- Chain A: Y.15, F.46, S.47, N.48
Ligand excluded by PLIPNAG.18: 2 residues within 4Å:- Chain A: N.318, Q.567
Ligand excluded by PLIPNAG.19: 1 residues within 4Å:- Chain A: N.644
Ligand excluded by PLIPNAG.20: 3 residues within 4Å:- Chain A: N.696, N.697, G.1118
Ligand excluded by PLIPNAG.21: 2 residues within 4Å:- Chain A: A.693, N.1061
Ligand excluded by PLIPNAG.22: 1 residues within 4Å:- Chain A: N.603
Ligand excluded by PLIPNAG.23: 3 residues within 4Å:- Chain B: Y.15, F.46, N.48
Ligand excluded by PLIPNAG.24: 2 residues within 4Å:- Chain B: H.133, N.136
Ligand excluded by PLIPNAG.25: 3 residues within 4Å:- Chain B: N.318, Q.567, L.569
Ligand excluded by PLIPNAG.26: 1 residues within 4Å:- Chain B: N.644
Ligand excluded by PLIPNAG.27: 5 residues within 4Å:- Chain B: N.109, T.111, N.112, V.114, E.143
Ligand excluded by PLIPNAG.28: 2 residues within 4Å:- Chain B: N.603, T.605
Ligand excluded by PLIPNAG.29: 3 residues within 4Å:- Chain C: Y.15, F.46, N.48
Ligand excluded by PLIPNAG.30: 1 residues within 4Å:- Chain C: N.136
Ligand excluded by PLIPNAG.31: 1 residues within 4Å:- Chain C: N.644
Ligand excluded by PLIPNAG.32: 2 residues within 4Å:- Chain C: N.788, S.790
Ligand excluded by PLIPNAG.33: 4 residues within 4Å:- Chain C: N.109, A.110, T.111, N.112
Ligand excluded by PLIPNAG.34: 2 residues within 4Å:- Chain C: T.95, N.221
Ligand excluded by PLIPNAG.35: 3 residues within 4Å:- Chain B: D.783
- Chain C: N.696, N.697
Ligand excluded by PLIPNAG.36: 3 residues within 4Å:- Chain C: N.603, T.605, Q.631
Ligand excluded by PLIP- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Yang, Z. et al., A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variants. Signal Transduct Target Ther (2021)
- Release Date
- 2021-11-24
- Peptides
- Spike glycoprotein: ABC
n3113: DE - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
BB
AC
CD
VE
D
- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-3-2-mer
- Ligands
- 16 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)(Non-covalent)
- 20 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Yang, Z. et al., A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variants. Signal Transduct Target Ther (2021)
- Release Date
- 2021-11-24
- Peptides
- Spike glycoprotein: ABC
n3113: DE - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
BB
AC
CD
VE
D